449 related articles for article (PubMed ID: 11607819)
1. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins.
Ayton PM; Cleary ML
Oncogene; 2001 Sep; 20(40):5695-707. PubMed ID: 11607819
[TBL] [Abstract][Full Text] [Related]
2. Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis.
Ono R; Nakajima H; Ozaki K; Kumagai H; Kawashima T; Taki T; Kitamura T; Hayashi Y; Nosaka T
J Clin Invest; 2005 Apr; 115(4):919-29. PubMed ID: 15761502
[TBL] [Abstract][Full Text] [Related]
3. Structure of AF3p21, a new member of mixed lineage leukemia (MLL) fusion partner proteins-implication for MLL-induced leukemogenesis.
Sano K
Leuk Lymphoma; 2001 Aug; 42(4):595-602. PubMed ID: 11697487
[TBL] [Abstract][Full Text] [Related]
4. The small oligomerization domain of gephyrin converts MLL to an oncogene.
Eguchi M; Eguchi-Ishimae M; Greaves M
Blood; 2004 May; 103(10):3876-82. PubMed ID: 14751928
[TBL] [Abstract][Full Text] [Related]
5. A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL.
DiMartino JF; Miller T; Ayton PM; Landewe T; Hess JL; Cleary ML; Shilatifard A
Blood; 2000 Dec; 96(12):3887-93. PubMed ID: 11090074
[TBL] [Abstract][Full Text] [Related]
6. MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function.
So CW; Cleary ML
Mol Cell Biol; 2002 Sep; 22(18):6542-52. PubMed ID: 12192052
[TBL] [Abstract][Full Text] [Related]
7. The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis.
Luo RT; Lavau C; Du C; Simone F; Polak PE; Kawamata S; Thirman MJ
Mol Cell Biol; 2001 Aug; 21(16):5678-87. PubMed ID: 11463848
[TBL] [Abstract][Full Text] [Related]
8. Common mechanism for oncogenic activation of MLL by forkhead family proteins.
So CW; Cleary ML
Blood; 2003 Jan; 101(2):633-9. PubMed ID: 12393557
[TBL] [Abstract][Full Text] [Related]
9. The ENL moiety of the childhood leukemia-associated MLL-ENL oncoprotein recruits human Polycomb 3.
García-Cuéllar MP; Zilles O; Schreiner SA; Birke M; Winkler TH; Slany RK
Oncogene; 2001 Jan; 20(4):411-9. PubMed ID: 11313972
[TBL] [Abstract][Full Text] [Related]
10. The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10.
DiMartino JF; Ayton PM; Chen EH; Naftzger CC; Young BD; Cleary ML
Blood; 2002 May; 99(10):3780-5. PubMed ID: 11986236
[TBL] [Abstract][Full Text] [Related]
11. Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis.
Daser A; Rabbitts TH
Genes Dev; 2004 May; 18(9):965-74. PubMed ID: 15132992
[No Abstract] [Full Text] [Related]
12. Malignant hematopoietic cell lines: in vitro models for the study of MLL gene alterations.
Drexler HG; Quentmeier H; MacLeod RA
Leukemia; 2004 Feb; 18(2):227-32. PubMed ID: 14671638
[TBL] [Abstract][Full Text] [Related]
13. Tet1 is not required for myeloid leukemogenesis by MLL-ENL in novel mouse models.
Ono R; Masuya M; Inoue N; Shinmei M; Ishii S; Maegawa Y; Maharjan BD; Katayama N; Nosaka T
PLoS One; 2021; 16(3):e0248425. PubMed ID: 33705482
[TBL] [Abstract][Full Text] [Related]
14. A novel chromosomal inversion at 11q23 in infant acute myeloid leukemia fuses MLL to CALM, a gene that encodes a clathrin assembly protein.
Wechsler DS; Engstrom LD; Alexander BM; Motto DG; Roulston D
Genes Chromosomes Cancer; 2003 Jan; 36(1):26-36. PubMed ID: 12461747
[TBL] [Abstract][Full Text] [Related]
15. Establishment of an inducible expression system of chimeric MLL-LTG9 protein and inhibition of Hox a7, Hox b7 and Hox c9 expression by MLL-LTG9 in 32Dcl3 cells.
Joh T; Hosokawa Y; Suzuki R; Takahashi T; Seto M
Oncogene; 1999 Jan; 18(4):1125-30. PubMed ID: 10023690
[TBL] [Abstract][Full Text] [Related]
16. t(10;11)-acute leukemias with MLL-AF10 and MLL-ABI1 chimeric transcripts: specific expression patterns of ABI1 gene in leukemia and solid tumor cell lines.
Shibuya N; Taki T; Mugishima H; Chin M; Tsuchida M; Sako M; Kawa K; Ishii E; Miura I; Yanagisawa M; Hayashi Y
Genes Chromosomes Cancer; 2001 Sep; 32(1):1-10. PubMed ID: 11477655
[TBL] [Abstract][Full Text] [Related]
17. The leukemogenic fusion of MLL with ENL creates a novel transcriptional transactivator.
Schreiner SA; García-Cuéllar MP; Fey GH; Slany RK
Leukemia; 1999 Oct; 13(10):1525-33. PubMed ID: 10516753
[TBL] [Abstract][Full Text] [Related]
18. Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes.
Biswas D; Milne TA; Basrur V; Kim J; Elenitoba-Johnson KS; Allis CD; Roeder RG
Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15751-6. PubMed ID: 21896721
[TBL] [Abstract][Full Text] [Related]
19. Chimeric MLL products with a Ras binding cytoplasmic protein AF6 involved in t(6;11) (q27;q23) leukemia localize in the nucleus.
Joh T; Yamamoto K; Kagami Y; Kakuda H; Sato T; Yamamoto T; Takahashi T; Ueda R; Kaibuchi K; Seto M
Oncogene; 1997 Oct; 15(14):1681-7. PubMed ID: 9349501
[TBL] [Abstract][Full Text] [Related]
20. Frat2 mediates the oncogenic activation of Rac by MLL fusions.
Walf-Vorderwülbecke V; de Boer J; Horton SJ; van Amerongen R; Proost N; Berns A; Williams O
Blood; 2012 Dec; 120(24):4819-28. PubMed ID: 23074275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
